Literature DB >> 1517371

Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly.

P J Ho1, R D Friberg, A L Barkan.   

Abstract

In acromegaly, GH hypersecretion occurs despite elevated insulin-like growth factor-I (IGF-I) levels, implying defective IGF-I feedback. To study the possible mechanisms of defective IGF-I negative feedback in acromegaly, we assessed parameters of pulsatile GH secretion during fasting-induced decrease in plasma IGF-I. Seven patients with active acromegaly and six normal controls were fasted for 6 days and GH secretory profiles were obtained by frequent (every 10 min) blood sampling for 24 h and analyzed by Cluster. Fasting resulted in similar decreases in IGF-I, body weight, and blood glucose levels, and increases in free fatty acid and beta-hydroxybutyrate in all subjects. Normal subjects showed increases in 24-h total and pulsatile GH production, GH pulse frequency, maximal pulse amplitude, interpulse and nadir levels, implying suppression of hypothalamic somatostatin secretion and increase in GH-releasing hormone (GHRH) pulse frequency. In acromegalic patients, GH (and, by inference, GHRH) pulse frequency was unchanged. Three patients had increases in GH production, interpulse, and nadir levels similar to the normals while the other four had no change or paradoxical decreases in these parameters. Percentage change in GH production was highly correlated with percentage change in interpulse and nadir levels in both normals and patients. Mean GH response to GHRH (0.33 micrograms/kg iv) did not change significantly in any group as a result of fasting. Our data suggest that in healthy humans IGF-I negative feedback on GH secretion involves suppression of GHRH pulse frequency. GH (and, by inference, GHRH) pulse frequency is resistant to decrease in IGF-I in acromegaly, suggesting that lowered sensitivity of GHRH neurons to IGF-I may be the mechanism of high GH pulse frequency in this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517371     DOI: 10.1210/jcem.75.3.1517371

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  GH receptor antagonist: mechanism of action and clinical utility.

Authors:  Sowmya K Surya; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

2.  Role of Glucocorticoids in Fasting-induced Changes in Hypothalamic and Pituitary Components of the Growth Hormone (GH)-axis.

Authors:  Eunhee Kim; Sanghee Seo; Hyunju Chung; Seungjoon Park
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

3.  Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release.

Authors:  M L Hartman; S M Pincus; M L Johnson; D H Matthews; L M Faunt; M L Vance; M O Thorner; J D Veldhuis
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

4.  Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models.

Authors:  Katica Bajuk Studen; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958

Review 5.  Current diagnosis of acromegaly.

Authors:  Rocio A Cordero; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 6.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

7.  The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects.

Authors:  Sowmya Surya; Jeffrey F Horowitz; Naila Goldenberg; Alla Sakharova; Matthew Harber; Andrea S Cornford; Kathy Symons; Ariel L Barkan
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

Review 8.  Pharmacological therapy for acromegaly: a critical review.

Authors:  Alex F Muller; Aart Jan Van Der Lely
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. Involvement of hypothalamic somatostatin.

Authors:  M Bermann; C A Jaffe; W Tsai; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

10.  Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly.

Authors:  S Grottoli; V Gasco; A Mainolfi; G Beccuti; G Corneli; G Aimaretti; C Dieguez; F Casanueva; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.